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Murine Immune Responses to Virus-Like Particle-Associated Pre- and
Postfusion Forms of the Respiratory Syncytial Virus F Protein
Lori McGinnes Cullen, Madelyn R. Schmidt, Sarah A. Kenward, Robert T. Woodland, Trudy G. Morrison
Department of Microbiology and Physiological Systems, Program in Immunology and Microbiology, University of Massachusetts Medical School, Worcester,
Massachusetts, USA
ABSTRACT
Virus-like particles (VLPs) built on the Newcastle disease virus (NDV) core proteins, NP andM, and containing two chimeric
proteins, F/F and H/G, composed of respiratory syncytial virus (RSV) fusion protein (F) and glycoprotein (G) ectodomains fused
to the transmembrane and cytoplasmic domains of the NDV F and HN proteins, respectively, stimulate durable, protective RSV
neutralizing antibodies in mice. Here, we report the properties of VLPs constructed to contain mutant RSV F protein ectodo-
mains stabilized in prefusion (pre-F/F) or postfusion (post-F/F) configurations. The structures of the chimeric proteins assem-
bled into VLPs were verified immunologically by their reactivities with a conformationally restricted anti-F protein monoclonal
antibody. Following immunization of mice, without adjuvant, pre-F/F-containing VLPs induced significantly higher neutraliz-
ing antibody titers than the post-F/F-containing VLPs or the wild-type F/F-containing VLPs after a single immunization but not
after prime and boost immunization. The specificities of anti-F IgG induced by the twomutant VLPs were assessed by enzyme-
linked immunosorbent assay (ELISA) using soluble forms of the prefusion and postfusion forms of the F protein as targets.
While both types of VLPs stimulated similar levels of IgG specific for the soluble postfusion F protein, titers of IgG specific for
prefusion F induced by the pre-F/F-containing VLPs were higher than those induced by post-F/F-containing VLPs. Thus, VLPs
containing a stabilized prefusion form of the RSV F protein represent a promising RSV vaccine candidate.
IMPORTANCE
The development of vaccines for respiratory syncytial virus has been hampered by a lack of understanding of the requirements
for eliciting high titers of neutralizing antibodies. The results of this study suggest that particle-associated RSV F protein con-
taining mutations that stabilize the structure in a prefusion conformationmay stimulate higher titers of protective antibodies
than particles containing F protein in a wild-type or postfusion conformation. These findings indicate that the prefusion F pro-
tein assembled into VLPs has the potential to produce a successful RSV vaccine candidate.
Human respiratory syncytial virus (RSV) is themost significantcause of acute viral respiratory disease in infants and young
children (1). There are from 34 to 65 million RSV infections re-
sulting in acute lower respiratory disease requiring hospitalization
and 160,000 to 199,000 deaths per year worldwide (2). Elderly
populations are also at significant risk for serious RSV disease. In
the United States, the virus accounts for 10,000 deaths and 14,000
to 60,000 hospitalizations per year among individuals more than
64 years of age (3–5). Indeed, RSV infection of this population is at
least as significant as influenza virus infections. RSV infections
result in high mortality rates in immunocompromised popula-
tions, particularly stem cell transplant recipients (6) and individ-
uals with cardiopulmonary diseases (7). Despite the significance
of RSV disease in different populations, there are no vaccines
available.
Failure to develop a licensed RSV vaccine is not due to lack of
effort as numerous vaccine candidates have been characterized in
preclinical and clinical studies spanning 5 decades (summarized
in references 8 to 9). While many problems have uniquely hin-
dered RSV vaccine development, amajor hurdle has been a lack of
understanding of requirements for generation of protective im-
munity to RSV infection. Many vaccine candidates are protective
in animal models and, while stimulating antibody responses in
humans, have failed to induce high levels of neutralizing antibod-
ies and protection from virus challenge in human trials (reviewed
in references 10 and 11). Although there are likely many reasons
for these observations, one important issue has been a lack of clear
understanding of the most effective form of the RSV antigens,
particularly the F protein, for stimulating potent neutralizing
antibodies.
The paramyxovirus F protein is folded into a metastable con-
formation and upon fusion activation refolds, through a series of
conformational intermediates, into the postfusion conformation,
which is structurally very different from the prefusion form (12–
19). While it is logical to assume that the prefusion form of F
protein should bemore effective in stimulating optimally neutral-
izing antibodies, recent structural studies have shown that the
postfusion form of the F protein contains at least some epitopes
recognized by neutralizing monoclonal antibodies (17, 18). Thus,
it has been argued that a postfusion F protein will stimulate pro-
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tection (20), and this form of F protein is now in clinical trials. In
contrast, Magro et al. reported that a significant proportion of
neutralizing antibodies in human or rabbit anti-RSV immune se-
rum do not bind to the postfusion F protein (21). These authors
have suggested that themajority of effective neutralizing antibody
binding sites reside on the prefusion F protein and not on the
postfusion form. Extending these studies, McLellan and col-
leagues solved the crystal structure of a prefusion form of the RSV
F protein ectodomain and demonstrated that this form of the
protein contained an antigenic site  not present on the postfu-
sion form of the protein (19). Furthermore, monoclonal antibod-
ies specific for this site neutralized RSV at significantly lower con-
centrations than antibodies specific for sites present on both the
pre- and postfusion forms of the protein. In a groundbreaking
study, McLellan et al. (22) identified mutations in the F protein
ectodomain that stabilized the prefusion form of the protein and
reported that soluble forms of stabilized prefusion F protein, in
the presence of adjuvant, stimulated significantly higher neutral-
izing antibody titers in both mice and nonhuman primates than
postfusion forms.
Virus-like particles (VLPs) are increasingly recognized as safe,
effective vaccines for viral diseases (23). VLPs are virus-sized par-
ticles composed of repeating structures on their surfaces and in
their cores, structures that mimic those of infectious viruses and
contribute to their very potent immunogenicity (23–25). VLPs are
formed by the assembly of viral structural proteins and sometimes
lipids into particles but without the incorporation of the viral
genome. Thus, VLPs are incapable ofmultiple rounds of infection
typical of an infectious virus. The surface glycoproteins of envel-
oped viruses are folded and inserted into VLP membranes typical
of a virus; thus, antigenic sites are retained, and no inactivation is
required.
We have recently described a novel, enveloped RSV virus-like
particle that stimulates protective immune responses in mice (26,
27). These VLPs were formed with the structural core proteins,
nucleocapsid protein (NP) and matrix (M) protein, of Newcastle
disease virus (NDV) and the ectodomains of the RSV F and G
proteins fused to the transmembrane (TM) and cytoplasmic tail
(CT) sequences of the NDV fusion (F) and hemagglutinin-neur-
aminidase (HN) proteins, respectively. These VLPs are highly im-
munogenic and stimulated both anti-F protein- and anti-G pro-
tein-specific antibodies in the absence of adjuvant (26, 27). We
have also reported that immunization of mice with three different
versions of these VLPs did not stimulate enhanced respiratory
disease upon RSV challenge (26–28) even at late times after im-
munization, in contrast to someother nonreplicatingRSVvaccine
candidates (29, 30).
Here, we report the assembly into these VLPs of the ectodo-
main of the RSV F protein containing mutations reported to sta-
bilize the prefusion or the postfusion form of this protein. We
compared in mice and without adjuvant the stimulation of neu-
tralizing antibody responses to the two forms of VLP-associated
RSV F proteins. Our results show that the VLP-associated prefu-
sion F protein stimulated significantly higher titers of neutralizing
antibodies than the VLP-associated postfusion F protein after a
single immunization.
MATERIALS AND METHODS
Cells, virus, and plasmids. ELL-0 cells (avian fibroblasts), Vero cells,
COS-7 cells, and Hep2 cells were obtained from the American Type Cul-
ture Collection. ELL-0 cells, Vero cells, COS-7 cells, and Hep2 cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with penicillin, streptomycin (Pen-Strep), and 5% (Vero cells) or 10%
fetal calf serum. RSV, A2 strain, was obtained from Robert Finberg.
The cDNAs encoding the Newcastle disease virus (NDV) NP and M
protein have been previously described (31). The construction, expres-
sion, and incorporation of the chimeric protein NDV HN/RSV G (H/G)
into VLPs (yielding VLP-H/G constructs) have been previously described
(26). The “wild-type” RSV F/NDV F (F/F) chimeric protein was con-
structed from a Gallus codon-optimized RSV F protein sequence
(GeneWiz). The sequence encoding the ectodomain of the RSV F protein
(amino acids 1 to 524) was fused to sequences encoding the NDV F pro-
tein transmembrane (TM) and cytoplasmic (CT) domains (amino acids
501 to 553) as previously described (27). Using a Stratagene QuikChange
II kit, four point mutations were introduced into the RSV sequence
(S155C, S190F, V207L, and S290C) to produce the DS-Cav1 F/F mutant.
To generate the pre-F/F chimeric protein (DS-Cav1-foldon-F/F), the
RSV F protein sequence encoding amino acids 1 to 520 was fused to a
Gallus codon-optimized sequence encoding the T4 fibritin trimerization
motif (foldon) (22, 32). RSV sequence encoding amino acids 521 to 524
(the membrane-proximal serine-threonine-rich region common to
paramyxovirus F proteins) was fused to the sequences encoding the NDV
TM and CT domains and ligated to the RSV F-foldon sequences.
To generate the post-F/F chimeric protein, sequences encoding amino
acids 137 to 146 were deleted from F/F using a Stratagene QuikChange
II kit.
The soluble pre-F was constructed using the sequences encoding the
RSV F ectodomain (amino acids 1 to 513) containing the DS-Cav1 mu-
tations fused to sequences (synthesized by GenWiz) encoding the foldon,
the thrombin cleavage site, Strep-Tag II, GSGSG linker, and six copies of
a His (6His) tag (22). The soluble postfusion F was constructed using
sequences encoding the RSV F protein ectodomain with the deletion of
amino acids 137 to 146 fused to sequences encoding the thrombin cleav-
age site, Strep-Tag II, GSGSG linker, and 6His tag (22).
Polyacrylamide gel electrophoresis, silver staining, and Western
analysis. Proteins in extracts, virus, or VLPs were resolved on 8% bis-Tris
gels (NuPage; Invitrogen). Silver staining of proteins in the polyacryl-
amide gels was accomplished as recommended by the manufacturer
(Pierce). Quantification of NP, M, different forms of F/F, and H/G pro-
teins in the polyacrylamide gels was accomplished byWestern blotting of
the proteins as well as protein standards as previously described (27, 33).
ForWestern analysis, proteins in the polyacrylamide gels were transferred
to polyvinylidene difluoride (PVDF)membranes using dry transfer (iblot;
Invitrogen). Proteins were detected in the blots using antibodies noted on
the figures and in the legends.
Antibodies. RSV Fmonoclonal antibody (MAb) clone 131-2A (Chemi-
con) was used in RSV plaque assays. Monoclonal antibody 1112, MAb
1200,MAb 1269, andMAb 1243, generous gifts of J. Beeler (34), andMAb
5C4, a generous gift of B. Graham (19), were used for fluorescence-acti-
vated cell sorting (FACS) analysis of transfected cells and enzyme-linked
immunosorbent assays (ELISAs) of VLPs and soluble F proteins. Anti-
RSV F protein HR2 antibody is a polyclonal antibody specific to the HR2
domain of the RSV F protein (27). Secondary antibodies against goat,
mouse, and rabbit IgG were purchased from Sigma.
Detection of cell surface-expressed chimeric F proteins. Biotinyla-
tion of surface-expressed F chimeric proteins was accomplished as previ-
ously described (35, 36). Cell surface biotinylated molecules were precip-
itated from cell lysates using NeutrAvidin-agarose (35, 36), and
precipitated F proteins were detected byWestern analysis using anti-RSV
F HR2 antibody.
Detection of antibody binding to surface-expressed chimeric proteins
was accomplished by flow cytometry. Avian cells transfected with
pCAGGS, pCAGGS-F/F, pCAGGS-DS-Cav1 F/F, pCAGGS–pre-F/F, or
pCAGGS–post-F/F were washed in phosphate-buffered saline (PBS), re-
moved fromplateswith cell dissociation buffer (Sigma), resuspended, and
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washed in FACS buffer (Hanks balanced salt solution; Gibco). Cells were
then incubated with mouse monoclonal antibody for 30 min on ice,
washed twice in FACS buffer, and incubated with goat anti-mouse IgG
coupled to Alexa Fluor 488 for 30 min on ice in the dark. After three
washes in FACS buffer, cells were resuspended in FACS buffer containing
propidium iodide (PI; 10g/ml). Flow cytometry was accomplished with
a MACSQuant Analyzer flow cytometer (Miltenyi Biotec), and data were
analyzed using FlowJo software gating onPI-negative, fluorescein isothio-
cyanate (FITC)-positive cells. Geometric mean fluorescence intensity
(MFI) of these cells was determined using FlowJo software.
VLP preparation, purification, and characterization. For prepara-
tions of VLPs to be used in ELISAs or as immunogens (VLP-H/Gpre-
F/F and VLP-H/Gpost-F/F), ELL-0 cells growing in T-150 flasks were
transfected with cDNAs encoding the NDV M protein, NP, the chimeric
protein H/G, and either pre-F/F or post-F/F as previously described (26,
27). At 24 h posttransfection, heparin was added to the cells at a final
concentration of 10 g/ml (26) to inhibit rebinding of released VLPs to
cells. At 48, 72, and 96 h posttransfection, cell supernatants were collected,
and VLPs were purified by sequential pelleting and sucrose gradient frac-
tionation as previously described (26, 27, 33). Concentrations of proteins
in the purified VLPs were determined by silver-stained polyacrylamide
gels and by Western analysis using marker proteins for standard curves
(27, 33).
Preparation of soluble F proteins. COS-7 cells transfected with
pCAGGS vector or with pCAGGS vector containing sequences encoding
the soluble pre-F protein or the soluble post-F protein were grown in
DMEM-high glucose, with glutamine, Na pyruvate, Pen-Strep, and insu-
lin, transferrin, and sodium selenite (ITS). At 48 h posttransfection, total
cell supernatants were collected, and cell debris was removed by centri-
fugation. Amounts of soluble F protein in the cell supernatants were de-
termined by Western blotting using anti-HR2 antibodies for detection.
Volumes of supernatant containing equivalent amounts of F protein were
used to coatmicrotiter wells. Similar volumes of supernatant from vector-
only-transfected cells were used to coat a third set of microtiter wells to
provide an indication of nonspecific binding to host cell soluble proteins.
F proteins were not purified from the cell supernatants in order to avoid
possible alteration of the conformation of the proteins during the purifi-
cation.
Quantification of soluble F protein and VLP-associated F protein.
Determinations of amounts of F protein in VLPs or in soluble F protein
preparations were accomplished by Western blotting using anti-HR2 an-
tibody for detection and comparing the signals obtained with a standard
curve of purified F proteins, as previously described (33).
Preparation of RSV, RSV plaque assays, and antibody neutraliza-
tion. RSV was grown in Hep2 cells (26, 27), and RSV plaque assays were
accomplished on Vero cells as previously described (26, 27).
Antibody neutralization assays in a plaque reduction assay have been
previously described (26, 27). Neutralization titer was defined as the di-
lution of serum that reduced the virus titer by 50%.
Animals, animal immunization, and RSV challenge. Four-week-old
female BALB/c mice from Jackson Laboratories or Taconic laboratories
were housed (groups of five) under pathogen-free conditions inmicroiso-
lator cages at the University of Massachusetts Medical Center animal
quarters. Protocols requiring open cages were accomplished in biosafety
cabinets. BALB/c mice were immunized by intramuscular (i.m.) inocula-
tion of 30 g of total VLP protein in 0.05 ml of TNE buffer (50 mM
Tris-HCl, pH 7.4, 150 mMNaCl, 5 mM EDTA) containing 10% sucrose.
For infection or challenges of mice with RSV, the animals were lightly
anesthetized with isoflurane and then infected by intranasal (i.n.) inocu-
lation of RSV (titers are indicated in the figure legends). All animal pro-
cedures and infections were performed in accordance with the University
of Massachusetts Medical School IACUC- and IBC-approved protocols.
Detection of virus in lung tissue. Four days after RSV challenge (37),
mice were sacrificed by CO2 asphyxiation. Lungs were removed asepti-
cally, and each lobe was placed separately in 0.5 ml of 30% sucrose in PBS
and frozen on dry ice. Lungs were stored at80°C. Upon thawing, lungs
were weighed and then homogenized in the storage buffer using aDounce
homogenizer (Kontes). The homogenate was centrifuged at 12,000 rpm
for 15 min, and the virus titer in the supernatant was determined by
plaque assay as described previously (26, 27).
ELISAprotocols. For determination of anti-F protein serum antibody
titers, blood was obtained from immunized animals by tail vein nicks and
centrifuged in BD Microtainer serum separator tubes to remove blood
cells. For ELISAs, wells of microtiter plates (Costar) were coated with cell
supernatant containing either soluble prefusion F protein or soluble post-
fusion F protein. Volumes containing equivalent amounts of the two
forms of soluble F protein were determined by reactivity to anti-HR2
antibody measured in Western blots. Negative controls were equivalent
volumes of supernatants from cells transfected with empty vector.
For antibody binding to VLPs, microtiter wells were coated with anti-
RSV antisera in 50 l of PBS for 24 to 30 h at 4°C. Wells were then
incubated in 100 l of PBS–1% bovine serum albumin (BSA) for 16 h at
4°C. Equivalent amounts of pre-F/F- or post-F/F-containing VLPs were
then added to the wells. Alternatively, equivalent amounts of VLPs in PBS
were added directly to the microtiter wells and incubated for 24 to 30 h at
4°C. Wells were then incubated in PBS–1% BSA for 16 h. After wells were
washed three times with PBS, different concentrations of selected anti-
bodies were added to each well, and wells were incubated for 2 h at room
temperature. After six washes in PBS, sheep anti-mouse antibody coupled
to horseradish peroxidase (HRP) or goat anti-rabbit antibody coupled to
HRP was added in 50 l of PBS–1% BSA and incubated for 1.5 h at room
temperature. Bound HRP was detected by the addition of 50 l of TMB
(3,3=5,5=-tetramethylbenzidine; Sigma) and incubation for 5 to 20 min at
room temperature until the development of blue pigment in thewells. The
reaction was stopped with 50 l of 1N sulfuric acid. Color was read in a
SpectraMax Plus plate reader (Molecular Devices) using SoftMax Pro
software.
Statistical analysis. Statistical analyses (Student t test) of data were
accomplished using GraphPad Prism, version 7, software.
RESULTS
Expression and antigenicity of mutant F proteins. To construct
NDV VLPs containing a stabilized prefusion form of the RSV F
protein and VLPs containing a stabilized postfusion F protein, we
modified our previously characterized RSV F/NDV F chimeric
protein (F/F) (27) in three ways. First, to produce a chimeric pro-
tein containing the stabilized prefusion RSV F protein ectodo-
main, we introduced four point mutations in the ectodomain
(S190F, V207L, S155C, and S290C), mutations previously identi-
fied by McLellan et al. (22) as stabilizing the secreted form of the
prefusion RSV F protein. McLellan and colleagues designated this
mutant protein DS-Cav1; thus, our mutant chimeric protein was
designated DS-Cav1 F/F (Fig. 1A). In a second construction, we
added to the DS-Cav1 F/F mutant a foldon sequence at the car-
boxyl terminus of the RSV F protein ectodomain, a sequence
found necessary for the stabilization of the secreted form of the
prefusion F protein trimer by McLellan et al. (19, 22) In this con-
struction, this sequence was placed in between the RSV F protein
ectodomain sequence and theNDVFprotein transmembrane do-
main sequence (Fig. 1A). The resulting chimeric protein is desig-
nated pre-F/F. We characterized the expression of both the DS-
Cav1 F/F and the pre-F/F in order to compare the effect of the
addition of the foldon sequence on expression of the chimeric
proteins.
To compare immune responses to the prefusion F protein with
responses to a postfusion form of the F protein, we constructed an
F/F chimeric protein containing a stabilized postfusion form of
the RSV F protein ectodomain. McLellan and colleagues have re-
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ported that deletion of amino acids 137 to 146 results in a stable
postfusion RSV F protein (38). Thus, we deleted this sequence
from wild-type F/F to create a post-F/F chimeric protein.
Incorporation of the mutant chimeric proteins into VLPs re-
quires their efficient expression on cell plasma membranes. To
determine if the alterations in the F/F chimeric protein affected
the cell surface expression of the chimeric proteins, surfaces of
cells expressing the wild-type and mutant chimeric proteins were
biotinylated, and after cell lysis, biotinylated molecules were pre-
cipitated with NeutrAvidin. The levels of biotinylated wild-type
and mutant F/F proteins in the precipitates were determined in
Western blots using an anti-RSVFprotein polyclonal antibody for
detection. Representative results of multiple experiments are
shown in Fig. 1B. Consistently, the levels of F/F, DS-Cav1 F/F,
pre-F/F, and post-F/F chimeric proteins were very similar. As ex-
pected, the pre-F/F migrates on polyacrylamide gels slightly more
slowly than the F/F due to the presence of the foldon sequence,
which adds 27 amino acids to the protein. The post-F/F protein
migrates slightly faster than F/F or the DS-Cav1 F/F due to the
deletion of amino acids 137 to 146.Wehave previously shown that
the F/F protein is proteolytically cleaved. Thus, the migration of
the DS-Cav1 F/F, the pre-F/F, and the post-F/F proteins on poly-
acrylamide gels is consistent with proteolytic cleavage of these
mutant proteins.
McLellan et al. have identified an antigenic site, termed site ,
which is unique to the prefusion form of the RSV F protein (19,
22). This site, which is present on the prefusion soluble F protein
but not the postfusion soluble F protein, has been defined by two
human anti-RSV Fmonoclonal antibodies and onemurine anti-F
monoclonal antibody, 5C4 (19, 22). To verify that chimeric pro-
teins DS-Cav1 F/F and pre-F/F contain this site and that the post-
F/F chimeric protein does not, the binding of anti-F 5C4 antibody
to cells transfectedwith cDNAs encoding the threemutant chime-
ric proteins as well as with the cDNA encoding the wild-type F/F
protein was determined by flow cytometry. Figure 2A to D show
representative profiles obtained. Figure 3A shows the geometric
mean fluorescence intensity after multiple separate determina-
tions. Clearly the DS-Cav1 F/F and the pre-F/F chimeric proteins
contain site  (Fig. 2B and C and 3A), whereas the post-F/F pro-
tein does not contain significant levels of this site (Fig. 2D and 3A).
The wild-type F/F also contains site  (Fig. 2A) but at a much
reduced level relative to DS-Cav1 F/F and pre-F/F. 5C4 binding to
DS-Cav1 F/F was comparable to that seen with pre-F/F (Fig. 2B
and C), suggesting that the foldon sequence has little influence on
expression of site  on cell surfaces in these chimeric proteins.
To determine the influence of these mutations on other previ-
ously defined RSV F protein antigenic sites, the binding of repre-
sentative anti-RSV F monoclonal antibodies, specific to sites I, II,
and IV (34), to the mutant and wild-type chimeric proteins ex-
pressed on cell surfaces was characterized. Figure 2E to H show
representative flow cytometry profiles for anti-F 1200, a site II
antibody. Additional determinations using this antibody as well as
antibodies from sites I, II, and IV are shown as the average geo-
metricmean fluorescence intensity (MFI) in Fig. 3B to E.With the
exception of anti-F 1112, there was no statistical difference in the
binding of monoclonal antibodies to sites I, II, and IV to cells
expressing F/F, pre-F/F, or post-F/F chimeric proteins. These re-
sults are consistent with the previous conclusion that both the
post- and prefusion forms of the RSV F protein contain antigenic
sites I, II, and IV (18, 19).
Characterization of virus-like particles containing pre-F/F
and post-F/F chimeric proteins. To prepare VLPs containing the
prefusion or postfusion forms of the RSV F protein ectodomain,
ELL-0 cells were transfected with plasmids encoding NDVMpro-
tein, NDV NP, the H/G chimeric protein (26), and either the
pre-F/F or the post-F/F chimeric protein. VLPs were harvested
and purified from the supernatants of these transfected cells as we
have previously described (26, 27, 39). Because the DS-Cav1 F/F
and the pre-F/F proteins contained similar levels of site  and
because the two proteins were expressed on cell surfaces at similar
levels, we focused on producing VLPs with the pre-F/F because
addition of the foldon sequence had the potential to increase the
stability of the prefusion form of the RSV F protein ectodomain
during preparation and purification of VLPs as well as immuni-
zation.
Figure 4 shows the characterization of the protein content of
the resulting VLPs. Panel A shows aWestern blot detecting RSV F
protein content in equivalent amounts (lanes 3 and 4) of total VLP
protein using an anti-RSV F protein polyclonal peptide antibody
for detection. To compare the efficiencies of chimeric protein in-
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FIG 1 Expression of wild-type andmutant chimeric proteins. (A) Diagram of
the wild-type chimeric protein (F/F) and three chimeric proteins with muta-
tions in the RSV F protein ectodomain. DS-Cav1 F/F contains four point
mutations, S155C, S190F, V207L, and S290C (gray arrows). Pre-F/F contains
the mutations in DS-Cav1 F/F as well as the foldon (F) sequence inserted
between the RSV F protein ectodomain and the NDV TM domain. Post-F/F
contains a deletion of sequences encoding amino acids (aa) 137 to 146. TM,
NDV F protein transmembrane domain; CT, NDV F protein cytoplasmic do-
main. Black arrows indicate RSV F protein cleavage sites. (B) Surface expres-
sion of chimeric F proteins. Avian cells (1  105 cells) transfected with
pCAGGS vector (V) or pCAGGS containing the gene encoding F/F, DS-Cav1
F/F, pre-F/F, or post-F/F were biotinylated and then lysed. Biotinylated mol-
ecules were precipitated and then denatured and reduced, and chimeric pro-
teins in the precipitate were detected byWestern blotting using anti-RSVHR2
antibody, which detects the F1 protein. The figure shows the results of one of
three comparable experiments.
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corporation into the VLPs, the NDV NP protein content of each
VLP preparation was determined by Western blotting using anti-
NDV antibody (Fig. 4B). Clearly, the VLPs contained similar lev-
els of NP (lanes 3 and 4), and the ratios of RSV chimeric F proteins
to NDV NP protein in each VLP preparation were similar, indi-
cating that the efficiencies of pre-F/F and post-F/F chimeric pro-
tein incorporation into the VLPs were similar. As shown in Fig.
4C, there was no differential effect of the mutant F proteins on
A
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FIG 2 Detection of monoclonal antibody binding to avian cells expressing chimeric F proteins. Representative monoclonal antibody binding to chimeric F
protein-expressing cells was detected by flow cytometry. Avian cells transfected with empty vector pCAGGS or pCAGGS containing the gene encoding the F/F,
the DS-Cav1 F/F, the pre-F/F, or the post-F/F chimeric protein were incubated withMAb anti-F 5C4 antibody orMAb anti-F 1200. (A toD) Binding to anti-5C4
antibody. (E to H) Binding to MAb anti-F 1200. Antibody binding to cells transfected with empty vector is shown in the gray peaks.
FIG 3 Quantification of monoclonal antibody binding to cells expressing chimeric proteins. Quantifications of the geometric mean fluorescence intensity in
multiple experiments (three to five) was accomplished by analysis of flow cytometry profiles, as shown in Fig. 2, using FlowJo software. Antibodies and sites are
as indicated on the figure.
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H/G chimeric protein incorporation into VLPs. Figure 4D shows
the silver stain of a polyacrylamide gel containing total proteins in
the VLP preparations. The levels of NDVMprotein, as well as NP,
in the VLPs were similar (lanes 3 and 4), supporting the conclu-
sion that the efficiencies of assembly of the pre-F and the post-F
proteins into VLPs were similar. In addition, there is little detect-
able host protein content in these VLPs.
Antibody binding to purified VLPs.To determine if assembly
of the chimeric F proteins into VLPs influences the F protein con-
formation and, therefore, the antigenic sites on the pre-F/F or the
post-F/F chimeric protein, binding of representative monoclonal
antibodies to the VLPs was characterized. In an ELISA, the bind-
ing of increasing amounts of representative monoclonal antibod-
ies to VLPs bound to microtiter plates was determined. Amounts
of VLPs containing equivalent levels of F protein, determined by
Western blotting as shown in Fig. 4, were bound to microtiter
wells. Figure 5A shows the binding of the VLPs to a polyclonal
antibody raised against the HR2 (HRB) domain of the RSV F
protein, a domain present in both chimeric proteins. Clearly the
levels of binding were similar, indicating that amounts of VLP
loaded on the plates were equivalent. Fig. 5B shows the binding to
the two VLPs of anti-F 5C4, the antibody specific to the prefusion
site. VLPs containing the pre-F/F bound this antibody while the
VLPs containing the post-F/F chimeric protein did not, indicating
that the VLP-associated pre-F/F chimeric protein retained site 
during assembly and purification of the VLPs and that the post-
F/F chimeric protein did not acquire this site.
We also measured binding of representative antibodies to sites
I, II, and IV to both types of VLPs (Fig. 5C to G). Consistently, we
found that none of the monoclonal antibodies bound to VLPs
containing the pre-F/F at levels comparable to binding to VLPs
containing the post-F/F chimeric protein. Binding of the antibod-
ies to the pre-F/F- or post-F/F-containing VLPs was saturated at
similar antibody concentrations, but the total binding at satura-
tion to the pre-F/F-containing VLPs was lower. This result was
obtained in at least four separate experiments. In the experiment
shown, the VLPs were bound to plates previously coated with
anti-RSV polyclonal antibody. Experiments in which the VLPs
were directly bound to microtiter wells were also conducted (data
not shown). Virtually identical results were obtained using both
protocols.
Because the levels of binding of the antibodies to sites I, II, and
IV to surfaces of cells transfected with pre-F/F or post-F/F were
virtually the same but binding to VLPs was not, we considered the
possibility that the presence of the H/G chimeric protein in the
VLPs affected the binding of antibodies to the RSV F protein se-
quences. To test this possibility, we determined binding of anti-
bodies to surfaces of cells transfected with cDNAs encoding the
H/G chimeric protein and either the pre-F/F or post-F/F protein.
Figure 6 shows that the coexpression of the H/G chimeric protein
in cells with either chimeric RSV F protein had little effect on the
binding of antibodies to site I or II. Thus, expression of the H/G
chimeric protein did not affect monoclonal antibody binding to
either chimeric F protein expressed on cell surfaces.
Anti-F protein IgG immune responses to the VLPs.We next
compared the ability of the two different VLPs to stimulate anti-
RSV F protein antibody responses. Groups of five BALB/c mice
were immunized with either VLP-H/Gpre-F/F or VLP-H/
Gpost-F/F or sham immunized with buffer, and sera were har-
vested by tail vein bleeding at different times after the prime im-
munization. Another group was infected intranasally (i.n.) with
RSV. At 118 or 109 days post-prime immunization, respectively,
the animals were boosted, and sera were harvested after 2 weeks.
Sera obtained from the five mice at each time point were pooled
for determination of anti-F protein IgG responses. To measure
specificity of these responses induced by the prefusion and post-
fusion forms of the F protein, we prepared soluble versions of both
forms to use as targets in ELISAs as previously described (18, 22).
To eliminate any conformational changes that may occur during
purification,we used unpurified supernatants of cells secreting the
soluble F proteins. To verify the conformation of these soluble
forms of F protein, the binding of representative anti-F monoclo-
nal antibodies to these secreted proteins was characterized by
ELISA. Equivalent amounts of the two forms of soluble RSV F
protein, as determined byWestern blotting, were bound tomicro-
titer plates, and, indeed, there were similar levels of binding of
anti-RSV F protein HR2 antibody to both forms of soluble pro-
tein, verifying that equivalent amounts of F protein bound to the
plates (Fig. 7A). That these soluble F proteins retained antigenic
properties reported for the soluble pre- and postfusion forms
of F protein is shown by the binding of soluble pre-F to anti-F
5C4 and the failure of soluble post-F to bind this antibody (Fig.
7B). Thus, the preparation of soluble forms of the RSV F pro-
tein did not impair the conformation of the pre-F protein, nor
did the preparation of post-F protein result in the acquisition
of this site. In addition, and as reported previously (18, 19, 38),
the soluble pre-F protein contained antigenic sites I, II, and IV
as did the soluble post-F protein (Fig. 7C to F). However, an-
tibodies to sites I, II, and IV did not bind to the soluble pre-F
FIG 4 Proteins in VLPs. VLPs harvested from cells expressing the NDV NP,
M, and H/G chimeric proteins as well as the pre-F/F or the post-F/F protein
were purified, and proteins in theVLPswere characterized byWestern blotting
(A to C) and silver staining (D). Labels at the top of panels indicate the chime-
ric F protein in the VLPs shown. Lanes 2 in panels A, B, and D contained twice
the VLP F protein content of lanes 3 and 4, determined in a preliminaryWest-
ern blot, in order to demonstrate that differences in protein content could be
detected. (A) RSV F protein content detected with anti-RSV HR2 peptide
antibody. Lane 1, purified RSV F (Novavax, Inc.). (B) NDV NP protein con-
tent detected with polyclonal anti-NDV. (C) RSV H/G detected with poly-
clonal anti-RSV antibody (which does not detect F sequences [27]). Lanes 1
and 2 contained equivalent amounts of VLPs as determined by F protein con-
tent. (D) Silver stain of proteins in VLPs or NDV. NP, NDV nucleocapsid
protein; M, NDV membrane protein; H/G, chimeric protein containing RSV
G protein ectodomain. All samples were boiled and reduced in sample buffer
containing -mercaptoethanol prior to electrophoresis.
McGinnes Cullen et al.
6840 jvi.asm.org July 2015 Volume 89 Number 13Journal of Virology
 o
n
 April 6, 2016 by UNIV O
F M
ASS M
ED SCH
http://jvi.asm.org/
D
ow
nloaded from
 
protein at levels typical of the soluble post-F protein, a result
similar but not identical to the differential binding to VLP-
associated pre-F and post-F proteins.
To measure specificity of antibodies in murine serum after
VLP immunization or RSV infection, the soluble F proteins were
used as targets in ELISAs (Fig. 8). After the prime immunization,
the levels of post-F-specific IgG in sera frommice immunizedwith
VLP-H/Gpre-F/F were similar to levels stimulated by VLP-H/
Gpost-F/F and levels stimulated by RSV infection (Fig. 8A and
C). After the boost immunization, the VLP-H/Gpost-F/F
sera contained slightly higher levels of post-F protein-specific
IgG than sera from VLP-H/Gpre-F/F-immunized or RSV-
infected mice, but these differences were not statistically signif-
icant (Fig. 8C). In contrast, after both the prime and boost
immunizations, there were significantly higher titers of pre-F-
specific anti-F IgG in sera obtained from VLP-H/Gpre-F/F-
immunized mice than in sera obtained from VLP-H/Gpost-
F/F-immunized mice (Fig. 8B and D).
RSV infection induced levels of antibodies that bound to the
soluble prefusion F protein at levels similar to those induced by
the post-F/F-containing VLPs. However, sera from all three
groups of immunizedmice contained overall lower levels of anti-F
FIG 5 Monoclonal antibody binding to purified VLPs. Pre-F/F- and post-F/F-containing VLPs containing equivalent amounts of F protein, as determined by
Western blotting as described in the legend of Fig. 4, were bound tomicrotiter plates as described inMaterials andMethods. Increasing amounts of representative
monoclonal antibodies were bound to the plates, and binding was detected using anti-mousemonoclonal antibody, as described inMaterials andMethods. That
virtually the same amounts of F protein-containing VLPs were bound to the plates is shown in panel A, in which RSV F protein sequences were detected with
anti-RSV HR2 antibody. Antibodies (Abs) and sites are as indicated on the figure. Results are representative of four separate determinations.
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IgG antibodies that would bind to the prefusion soluble F protein
than levels that would bind the postfusion soluble F protein.
Neutralizing antibody responses stimulated by the VLPs.To
determine the neutralizing antibody titer of sera obtained in rela-
tion to time after immunization with VLP-H/Gpre-F/F or VLP-
H/Gpost-F/F or after RSV infection, sera from each group of
animals were pooled and used in an in vitro plaque reduction
assay. Figure 9 shows that VLP-H/Gpre-F/F stimulated signifi-
cantly higher titers of neutralizing antibody than VLP-H/
Gpost-F/F after a single dose of VLPs (prime immunization). At
75 days postprime, the neutralization titers stimulated by the pre-
F/F- and post-F/F-containing VLPs were approximately 312 and
65 (log2 8.3 and 6, respectively), respectively. The boost signifi-
cantly increased the neutralizing antibody titer in mice immu-
nized with VLP-H/Gpre-F/F. The titer obtained at this time
pointwas approximately 4,000 (approximately 12 log2). The boost
with the post-F/F-containing VLPs also increased titers signifi-
cantly to approximately 2,700 (approximately 11.3 log2). Titers
after a single or double RSV infection were 74 and 465, respec-
tively.
Protection of immunized mice from RSV challenge. To de-
termine the protection from RSV replication afforded by VLP
immunization, the virus titers in lungs of immunized mice after
RSV challenge were determined by plaque assay (Fig. 10). Clearly
immunization with both VLP-H/Gpre-F/F and VLP-H/
Gpost-F/F protected mice from RSV replication upon chal-
lenge, as did RSV infection. This result was expected since we have
previously shown that the VLP-H/GF/F immunization pro-
tected mice from RSV replication upon challenge (27).
DISCUSSION
Recent studies of the RSV F protein have made it clear that most
previously tested RSV vaccine candidates contained predomi-
nantly the postfusion formof the F protein. It is also clear from the
seminal work ofMcLellan et al., (19, 22) andMagro et al. (21) that
the postfusion form of the RSV F protein is missing epitopes that
stimulate themost effective neutralizing antibodies in experimen-
tal animals. McLellan et al. (19, 22) defined one such epitope,
which they called , and showed that point mutations in the RSV
F protein ectodomain along with a trimerization domain (foldon)
derived fromphage T4 fibritin (22, 40) resulted in the stabilization
of the soluble form of the prefusion form of the RSV F protein.
We have previously shown that the RSV F protein and G pro-
tein ectodomain sequences, fused to the cytoplasmic and trans-
membrane domain sequences of the NDV F and HN proteins,
respectively, could be incorporated into VLPs formed with the
NDV NP and M protein and that these VLPs stimulated, in mu-
rine systems, protective, neutralizing antibody responses (27).
Furthermore, we also reported that the chimeric F protein con-
tained antigenic site  (28). However, the proportion of VLP-
associated chimeric F proteins containing this epitopewas unclear
as was the stability of prefusion F protein in these VLPs. It is
conceivable that injection of VLPs into an animalmay result in the
conversion of any VLP-associated prefusion forms to a postfusion
form and, thus, in a diminished stimulation of the more effective
neutralizing antibody responses. Thus, to stabilize the prefusion
form of the chimeric F protein in the ND VLPs, we introduced
point mutations in the RSV F protein ectodomain sequence, mu-
tations previously defined as stabilizing site (22). In addition, as
was done in the preparation of the soluble form of the prefusion F
protein (22), we added the foldon trimerization domain in be-
tween the RSV F and the NDV F sequences to further stabilize the
structure. In order to directly compare immune responses toVLPs
containing the prefusion F protein with responses to VLP-associ-
ated postfusion F protein, VLPs containing a stabilized postfusion
F protein were also prepared by introducing a deletion mutation
in the fusion peptide and HR1 (HRA) domain, a deletion that
favors the formation of the postfusion form of the RSV F (18).
The two forms of the mutant chimeric proteins were incorpo-
rated with similar efficiencies with respect to NP and M protein
content into ND VLPs, and the two chimeric proteins had no
differential effect on incorporation of the H/G chimeric protein.
Furthermore, the VLP-associated chimeric proteins differentially
bound an antibody specific for site , verifying their conforma-
tion. Surprisingly, however, antibodies specific to sites I, II, and IV
bound the twoVLPs differently. In all cases, binding of antibody at
saturation was lower for the pre-F/F-containing VLPs although
saturation was reached at similar antibody concentrations for the
twoVLPs.We considered the possibility that these results could be
due to the presence of theH/G chimeric protein, but no difference
in binding of anti-F monoclonal antibodies to surfaces of cells
expressing the F chimeric proteins in the presence or absence of
the H/G chimeric protein was observed. However, the packing of
the molecules on cell surfaces and on VLP surfaces may be very
different. Close packing of the pre-F/F with H/G protein in the
VLPsmaywell inhibit binding of antibodies to sites I, II, or IV. The
post-F/F proteinmay extend beyond theH/Gproteinmolecule on
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FIG 6 Effect of H/G protein expression on anti-F protein monoclonal anti-
body binding to avian cells expressing chimeric F proteins. Avian cells trans-
fected with empty vector pCAGGS or pCAGGS–pre-F/F in the presence or
absence of pCAGGS-H/G (A and C) or with pCAGGS–post-F/F in the pres-
ence or absence of pCAGGS-H/G (B and D) were incubated with MAb anti-
1112 (A and B) or MAb anti-1200 (C and D). Binding of anti-F monoclonal
antibodies was determined by flow cytometry. Gray peak, binding of antibody
to cells transfected with empty vector; black line, chimeric F-expressing cells in
the presence of H/G; gray line, chimeric F proteins expressed alone.
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VLP surfaces, making the sites more accessible to antibody bind-
ing. Indeed, studies of the structure of the G protein of human
metapneumovirus (hMPV), a closely related paramyxovirus, in-
dicated that the MPV G protein extends from the virion surface
somewhat beyond that predicted for the prefusion F protein while
the postfusion F protein would extend beyond the G protein (41).
Thus, it is possible that in VLPs the H/G chimeric protein limits
the accessibility of the prefusion F/F to antibody while having less
effect on site accessibility in the postfusion F/F protein. However,
it is also possible that the affinity of the monoclonal antibodies to
the prefusion F protein is lower than affinity to the postfusion F
protein.
In order to compare immune responses induced by the parti-
cle-associated pre-F/F and the post-F/F chimeric proteins, mice
were immunized, without adjuvant, with the two VLPs, and neu-
tralizing antibody titers, anti-F protein serum IgG responses, and
protection fromchallengewere assessed. The key results presented
here are the neutralizing antibody titers stimulated by the two
VLPs. It has been estimated that the protective threshold is a titer
of 1/100 (dilution resulting in 50% inhibition) (22) or a titer of 6
log2 (42). Significantly, after a single or prime immunization,
without adjuvant, the pre-F/F-containing VLPs stimulated neu-
tralizing antibody titers of approximately 312 and 324 (log2 of 8.3)
by days 75 and 90, respectively, while the titers stimulated by the
post-F/F-containing VLPs were significantly lower (65 and 150,
respectively) and very similar to neutralization titers induced after
a single immunization with VLPs containing the wild-type F/F
chimeric protein (27). Thus, VLPs containing a stabilized prefu-
sion F protein aremore effective in inducing neutralizing antibod-
ies after a single immunization than VLPs that contain chimeric
protein in primarily a post-F conformation.
A prime followed by a boost immunization with the pre-F/F-
containing VLPs resulted in titers of approximately 4,000 (12
log2). Interestingly, serum titers after a prime and boost immuni-
zation with the post-F/F-containing VLPs were also very high,
approximately 2,700 (11 log2). The neutralization titers after a
prime and boost with the post-F/F-containingVLPs can be due, in
part, to antibodies to the RSV G protein. In addition, it has also
been shown that monoclonal antibodies specific to sites I, II, and
IV on the F protein are neutralizing but at a much higher concen-
tration than antibodies to site (22). Therefore, after a prime and
boost with VLP-H/Gpost-F/F, the antibody titers to these sites
may well be high enough to neutralize virus effectively. Indeed, a
humanized monoclonal antibody, palivizumab, which is specific
FIG 7 Monoclonal antibody binding to soluble pre-F and post-F proteins. Soluble forms of the prefusion RSV F protein and the postfusion RSV F proteins as
well as cell supernatants fromempty vector-transfected cells, prepared as described inMaterials andMethods, were bound tomicrotiter plates and then incubated
with increasing amounts of representative monoclonal antibodies. Binding of antibodies was detected using anti-mouse IgG (or anti-rabbit IgG for panel A).
Antibodies and sites are as indicated on the figure. Results are representative of two separate determinations. OD, optical density.
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for site II, is an effective prophylactic for infants at risk for RSV
disease. Thus, immunization with pre-F/F-containing VLPs re-
sulted in the highest neutralizing antibody titers although the
post-F/F-containing VLPs after a boost were also effective in stim-
ulating high titers of neutralizing antibodies. A prime and boost of
RSV resulted in titers at 2 weeks postboost of approximately 465
(8.9 log2) and 1,200 after the subsequent RSV challenge, titers
significantly lower than those stimulated by either VLP type at
most time points. However, the route of immunization of RSV
was different, which may account for lower serum neutralizing
antibody titers.
McLellan et al. reported that a prime and boost immunization
ofmicewith soluble forms of the prefusion formof RSVF resulted
in neutralization titers of 4,000 (22). This result was obtained us-
ing an adjuvant and significantly more F antigen (10 g/animal
versus 3.8 g/animal) than we used in our VLPs. Titers after a
single immunization with soluble protein were not reported.
Thus, at lower antigen levels without adjuvant, the pre-F/F-con-
taining VLPs induced similar levels of neutralizing antibodies
as those reported for soluble forms of the prefusion form of the
protein with adjuvant after both a prime and boost. Interestingly,
titers after a prime-boost immunization with soluble postfusion F
protein were reported to be 600 (22) or 200 (20), considerably less
than those we observed with VLP-associated post-F/F protein.
This difference may be due to the presence of the G protein se-
FIG 8 IgG Immune responses to the pre-F/F- and post-F/F-containing VLPs.
BALB/c mice, in groups of five, were immunized i.m. with 30 g of VLP
protein/animal (3.8g of F protein) with either pre-F/F- or post-F/F-contain-
ing VLPs. Another group received buffer only, while a fourth group was in-
fected i.n. with RSV (1  106 PFU/mouse). Serum was harvested by tail vein
bleed at various times after the prime immunization. At day 118 (VLP-H/
Gpre-F/F) or 109 (VLP-H/Gpost-F/F), mice received a boost immuniza-
tion (10 g of VLP protein/mouse containing 1.25 g of F protein or 1 106
RSV PFU/mouse). Two weeks after boost, serum was harvested. At 18 days
after boost, animals were challenged with RSV, and 4 days after challenge they
were sacrificed for serum and lung harvest. (A and B) At each time point, sera
from each group were pooled, and amounts of total IgG that bound to the
soluble pre-F and of total IgG that bound to soluble post-F were determined as
described in Materials and Methods. (C and D) Total anti-F protein IgG in
serum of individual mice was determined for day 90, for 2 weeks postboost,
and for terminal bleeds. Graphs show the average anti-F IgG amount in serum
from individual mice, with variations indicated. For results using soluble
post-F as a target, differences between the results for three groups at day 90
and differences between the results for the groups at 2 weeks postboost or
in terminal bleeds are not statistically significant. Using soluble pre-F as a
target, differences between the results for all three groups at day 90 are
statistically significant. Differences between the results for pre- and post-
F/F VLP sera and differences between the results for pre-F/F VLP sera and
RSV sera at 2 weeks postboost are significant while the differences between
the results for post-F/F VLP sera and RSV sera are not. Arrows indicate
time of boost immunizations.
FIG 9 Neutralization titers in sera from immunized mice. Sera from each
group of immunized mice at each time point were pooled. The neutralization
titers were determined in a standard plaque reduction assay as described in
Materials andMethods. Titer was defined as the reciprocal of the dilution that
inhibitedRSVplaque formation by 50% (22). Results are the averages of two to
five separate determinations. Differences between the results for pre-F/F-con-
taining VLP sera and post-F/F-containing VLP sera at days 60, 75, and 90 are
significant (P 0.05).Differences between the results at 2weeks postboost and
in the terminal bleed are not significant.
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quences in the VLPs. However, such differences in responses to
soluble and particulate forms of an antigen have been repeatedly
observed in many systems. As discussed by Bachmann and col-
leagues (23, 25, 43), presentation of an antigen in a particulate
form and in an ordered array typical of a virus particle results in a
more effective immune response than one to soluble proteins, a
response that does not require the complications of adjuvants.
To assess total anti-F protein IgG responses specific for the
prefusion and postfusion F proteins, we first prepared the soluble
forms of pre-F and post-F proteins as targets in ELISAs, and their
differential binding to antibody specific to site  was verified.
Surprisingly, the reactivities of the soluble prefusion F protein to
antibodies to sites I, II, and IV were significantly different from
reactivities to comparable amounts of the soluble postfusion F
protein, results somewhat similar but not identical to those ob-
tained with VLP-associated chimeric proteins. In contrast to re-
sults of antibody binding to VLP-associated chimeric F proteins,
antibody binding to the soluble pre-F protein was saturated at
higher concentrations than binding to the soluble post-F protein.
These results suggest that the accessibility of the soluble prefusion
F protein to antibodies to sites I, II, and IV is less than that of the
soluble postfusion F protein. Alternatively, the conformation of
an antigenic site in the two differently folded forms of F is some-
what different, resulting in a different affinity of an antibody to
that site. It will be important for future improvements of vaccine
design to clarify the reasons for reduced binding of antibodies to
the prefusion F protein compared to binding to the postfusion F.
Immunization ofmicewith both types of VLPs induced similar
levels of IgG specific to the postfusion forms of F protein, indicat-
ing that both forms are similarly antigenic. After a prime and
boost, the levels of post-F-specific IgG stimulated by pre-F/F-con-
taining VLPs were slightly lower than those stimulated by compa-
rable amounts of post-F/F-containing VLPs, but the differences
were not statistically significant. Surprisingly, neither VLP type
induced pre-F-specific IgG at levels comparable to post-F protein-
specific IgG levels. This result, coupled with the results of our
antibody binding to VLP-associated pre-F/F and soluble pre-F
protein, suggests that antibody binding sites on the pre-F protein
are less accessible to antibody or, alternatively, that antibodies
have lower avidity to pre-F protein. The pre-F/F-containing VLPs
did stimulate significantly higher levels of antibody reactive to the
soluble prefusion F protein than the post-F/F-containing VLPs, a
result consistent with stimulation of antibody to sites not present
on the postfusion forms. However, it is also possible that this
difference is due, at least in part, to antibodies induced by the
foldon sequences present in the pre-F/F-containing VLPs and the
soluble pre-F protein target but not in the post-F/F-containing
VLPs or soluble post-F target.
RSV infection stimulated responses to the two forms of soluble
F, but the levels induced to both the pre- and postfusion targets
were similar to those induced by the VLPs containing the postfu-
sion F protein. This result is consistent with the report that puri-
fied RSV contains predominantly postfusion forms of F protein
(44).
All three immunizations resulted in protection of mice from
RSV replication upon RSV challenge. This result is not surprising
since we have shown that VLPs that stimulate considerably lower
titers of neutralizing antibody provide statistically significant pro-
tection in mice upon challenge (27). In addition, protection may
also be due in part to responses to the H/G chimeric protein pres-
ent in both VLPs.
Results presented here show that a prefusion F antigen associ-
ated with VLPs will stimulate high titers of neutralizing antibodies
and antibodies specific for the prefusion form of the RSV F pro-
tein. This form of the RSV F protein will also induce antibodies
specific for sites present on the postfusion form of the protein. A
humanized monoclonal antibody, palivizumab, which is specific
for site II (45, 46) has proven to be a useful prophylactic for RSV in
infants. Thus, inclusion of the prefusion form of the F protein in
virus-like particle RSV vaccine candidates should stimulate anti-
bodies to all sites associated with protective responses and en-
hance protective responses without the necessity of added adju-
vants.
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